O-RAN-ALLIANCE
16.8.2021 15:00:13 CEST | Business Wire | Press release
The O-RAN ALLIANCE welcomes 1&1 as its newest operator member, extending the world-wide community of 30 mobile network operators committed to deployment of open and intelligent Radio Access Networks (RAN).
The Third O-RAN Whitepaper Focuses on O-RAN Minimum Viable Plan and Acceleration towards Commercialization
Published on June 29, 2021, the whitepaper describes key areas to accelerate and enable the introduction of the rich capabilities of O-RAN Architecture in commercial networks. It also outlines a minimum viable set of end-to-end specifications for selected use cases to deploy a secure, multi-vendor interoperable network. The full whitepaper is available at our website .
O-RAN ALLIANCE Sets Cooperation with ETSI and TSDSI
To ensure compatibility and to avoid duplication of work, the O-RAN ALLIANCE’s specification effort builds on common standards and values alignment with other industry bodies.
On May 27, 2021, the O-RAN ALLIANCE signed a cooperation agreement with the European Telecommunications Standards Institute (ETSI). O-RAN ALLIANCE shares with ETSI a common objective to perform and promote regional and international standardization for 3GPP based technologies.
The O-RAN ALLIANCE also signed a Memorandum of Understanding with the Telecommunications Standards Development Society, India (TSDSI). It expresses mutual interest in cooperation to grow open interfaces and the open RAN ecosystem in the India subcontinent region.
New Open Test and Integration Centers (OTIC)
On June 28, 2021, the O-RAN ALLIANCE approved three new OTICs:
- European OTIC in Madrid hosted by Telefonica
- European OTIC in Paris hosted by Orange
- Auray OTIC and Security Lab (Taiwan) hosted by Auray Technology
The newly approved OTICs are widening the collaborative, open, and impartial working environment to ensure consistency and quality of testing of O-RAN products and solutions. See the full list of approved OTICs at our website .
New Standards Collaboration Copyright License (SCCL) to Simplify the Open Source Development
O-RAN ALLIANCE has introduced a new Standards Collaboration Copyright License (SCCL). The SCCL has been developed to simplify the process of producing open source SW based on standards, by defining a license that will make it easier for the open source community to use code-like sections of O-RAN specifications in their implementations.
“We believe that open source will play an important role in enabling open implementations, even if an operator never deploys stand-alone open source code in its network,” said Alex Jinsung Choi, Chief Operating Officer of the O-RAN ALLIANCE and SVP of Strategy and Technology Innovation, Deutsche Telekom. “The open source can help suppliers build their commercial implementations, and perhaps most importantly, it can also make it easier to achieve cross-vendor integration and interoperability between open RAN components by providing a reference implementation.”
The June 2021 O-RAN ALLIANCE Industry Summit Available for Replay
The O-RAN ALLIANCE Industry Summit on June 29 provided valuable insights on the latest O-RAN development, especially in terms of commercialization, security and performance. The 90-minute event is available for replay on demand at our website .
4th Release of Open Software for the RAN Developed by the O-RAN Software Community
The O-RAN Software Community (OSC or O-RAN SC) was formed in partnership with the Linux Foundation in April 2019, to support software development of open RAN solutions available to everyone.
The “D” release delivers major enhancements including support for closed-loop processing use cases, continued evolution of Non-Real-Time RAN Intelligent Control (Non-RT RIC) platform, new and enhanced xApps for the Near-Real-Time Radio Intelligent Controller (Near-RT RIC), as well as new performance monitoring and alarm support.
To deep-dive into the D release and to get the open software, please visit the O-RAN Software Community website .
"With the joint efforts from the mobile carriers, traditional vendors, and more technology partners onboard, the 4th release is the first try to get the full O-RAN software stack working, and in addition we can now declare it is a smart RAN," said Chih-Lin I, the Co-chair of O-RAN Technical Steering Committee. "We are glad to see major accomplishments in the D release, and that our lab now delivers a reliable environment for the software community to continue new feature implementation and integration test verification."
"Ericsson continues to be very active in O-RAN ALLIANCE making contributions to specifications and O-RAN architecture evolution,” said Per Beming, Head of Standard and Industry Initiatives at Ericsson. "In the OSC D release, Ericsson has continued as the key contributor to the Non-RT RIC project by further evolving support for the A1 interface, in addition to laying the foundations for Non-RT RIC automation applications and the R1 interface. Delivering a framework which supports rApp development is a key aspect of intent based management with the A1 interface, enabling more fine-grained intelligent control and optimization decisions.”
“We are excited to extend our contributions to another Linux Foundation project. Our most recent contributions towards the OAM component in the D-release of O-RAN SC demonstrate PANTHEON.tech's commitment to help our customers with the evolution and adoption of open-source projects," said Miroslav Miklus, Chief Product Officer at PANTHEON.tech.
”Making the RAN intelligent and context-aware is critically important for network optimization and automation. The focus of Samsung's O-RAN SC contribution has been towards enhancing the A1-Enrichment Information (A1-EI) & xAPP Framework. Overall, we believe that strengthening the O-RAN AI/ML Framework will play a big role in making operators achieve proactive closed-loop optimization and automation of RAN operations," said Dr. Sunghyun Choi, Corporate SVP and Head of Advanced Communications Research Center of Samsung Research, Samsung Electronics.
“Xoriant has participated in the O-RAN Software Community by contributing code to O1/VES interface of SMO,” said Girish Gaitonde, CEO of Xoriant. “We contributed to the initial implementation of the O-RAN O1/VES interface for OSC, with the idea to enable a close loop automation use-case between SMO and the other network functions such as O-DU, O-RU, O-CU and the Near RT-RIC.”
About O-RAN ALLIANCE
The O-RAN ALLIANCE is a world-wide community of 315 mobile operators, vendors, and research & academic institutions operating in the Radio Access Network (RAN) industry. As the RAN is an essential part of any mobile network, the O-RAN ALLIANCE’s mission is to re-shape the industry towards more intelligent, open, virtualized and fully interoperable mobile networks. The new O-RAN standards will enable a more competitive and vibrant RAN supplier ecosystem with faster innovation to improve user experience. O-RAN based mobile networks will at the same time improve the efficiency of RAN deployments as well as operations by the mobile operators. To achieve this, the O-RAN ALLIANCE publishes new RAN specifications, releases open software for the RAN, and supports its members in integration and testing of their implementations.
For more information please visit www.o-ran.org .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210816005392/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom